LRRK2 (Leucine-Rich Repeat Kinase 2)

📖 Wiki Page

gene2407 wordssynced 2026-04-02

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LRRK2 (Leucine-Rich Repeat Kinase 2) — Comprehensive Gene Review</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ENTITIES-LRRK2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>LRRK2 (Leucine-Rich Repeat Kinase 2) — Comprehensive Review</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=ENTITIES-LRRK2" target="_blank">Search NCBI</a></td>
</tr>
</table>

Overview

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multi-domain protein encoded by the LRRK2 gene (located at chromosome 12q12) that has emerged as one of the most important genetic contributors to Parkinson's disease (PD). Discovered in 2004 through linkage analysis of the "S TASK" family, LRRK2 mutations are now recognized as the most common cause of genetically determined PD, accounting for approximately 5-10% of familial cases and 1-5% of sporadic cases worldwide[@paisan-ruiz2019].

...

LRRK2 (Leucine-Rich Repeat Kinase 2)

Overview

LRRK2 is a member of the ROCO protein family, characterized by a unique architecture featuring multiple protein-protein interaction domains coupled with a central ROC (Ras of complex proteins) GTPase domain and a serine/threonine protein kinase domain. This complex domain structure suggests that LRRK2 functions as a molecular scaffold integrating multiple signaling pathways, making it a central player in neuronal function and survival[@walls2024].

The discovery of LRRK2 mutations causing PD sparked intense research into understanding the molecular mechanisms by which pathogenic variants lead to dopaminergic neuron degeneration. This work has revealed that LRRK2 affects multiple cellular processes including mitochondrial function, protein homeostasis, membrane trafficking, cytoskeletal dynamics, and neuroinflammation — all processes central to PD pathogenesis[@izzard2024].

Gene Structure and Mutations

Genomic Organization

The LRRK2 gene spans approximately 144 kb on chromosome 12q12 and consists of 51 exons encoding a 2,527 amino acid protein with a molecular weight of approximately 286 kDa. The gene exhibits typical mammalian gene structure with multiple splice variants, though the full-length isoform (isoform 1) is the predominant and most studied variant in the context of PD[@greggio2012].

Pathogenic Mutations

Over 100 LRRK2 variants have been identified, with approximately 10 of these confirmed as pathogenic based on segregation in PD families, absence in healthy controls, and functional validation. The most common pathogenic mutations include:

G2019S — The most frequent LRRK2 mutation, accounting for approximately 5% of familial PD worldwide and up to 40% of cases in certain populations such as North African Arabs and Ashkenazi Jews. This mutation occurs in the kinase domain (glycine 2019 to serine), leading to increased kinase activity. The G2019S mutation demonstrates incomplete age-dependent penetrance (approximately 30% by age 80), suggesting that additional genetic or environmental factors modify disease expression[@kalinderi2022].

R1441C/G/H — Mutations at arginine 1441 in the ROC GTPase domain. These variants reduce GTPase activity, potentially leading to enhanced downstream signaling. The R1441G mutation is particularly common in Basque families, where it represents a founder mutation with near-complete penetrance[@riviere2022].

N1437H — A less common GTPase domain mutation with strong pathogenic evidence.

Y1699C — Located in the WD40 repeat domain, this mutation disrupts protein-protein interactions.

I2020T — Found in a Japanese family (the "Kando" family), this kinase domain mutation has been associated with typical PD phenotype[@schneider2023].

The distribution of LRRK2 mutations varies geographically. G2019S is most prevalent in Mediterranean populations, while R1441 mutations are concentrated in Basque and other European populations. This geographic distribution provides insights into population history and founder effects[@paisan-ruiz2019].

Risk Variants

Beyond clearly pathogenic mutations, numerous LRRK2 variants have been identified as risk factors for sporadic PD through genome-wide association studies (GWAS). These common variants generally have small effect sizes but collectively contribute to population-attributable risk. The functional significance of most risk variants remains under investigation, though some may affect LRRK2 expression or splicing.

Protein Structure and Function

Domain Architecture

LRRK2 possesses a complex multi-domain architecture reflecting its role as a signaling hub[@walls2024]:

N-terminal Domain — Contains multiple leucine-rich repeats (LRR) involved in protein-protein interactions and substrate recognition.

ROC Domain (Ras of Complex Proteins) — A GTPase domain homologous to Ras proteins, but with unique features including GTP-dependent dimerization. The ROC domain functions as a molecular switch, cycling between active GTP-bound and inactive GDP-bound states.

COR Domain (C-terminal of ROC) — A conserved region unique to ROCO proteins that appears to coordinate ROC and kinase domain activities.

Kinase Domain — A serine/threonine protein kinase with similarity to the MAP kinase kinase kinases (MAP3Ks). The kinase domain is the therapeutic target for most LRRK2 inhibitors in development.

C-terminal WD40 Repeat — A beta-propeller structure involved in protein-protein interactions and substrate recruitment.

Biological Functions

LRRK2 is expressed throughout the brain, with highest levels in dopaminergic neurons of the substantia nigra pars compacta, cortical neurons, and cerebellar Purkinje cells. This expression pattern correlates with the brain regions most affected in PD[@esteban2022].

The protein localizes to multiple cellular compartments including:

Cytoskeleton — LRRK2 associates with microtubules and influences cytoskeletal dynamics. Pathogenic mutations disrupt microtubule stability and axonal transport.

Mitochondria — LRRK2 localizes to mitochondrial outer membrane and influences mitochondrial function, dynamics, and mitophagy. Mutations impair mitochondrial quality control mechanisms[@chen2022].

Synaptic terminals — LRRK2 is enriched at synapses where it regulates synaptic vesicle trafficking, dopamine release, and synaptic plasticity.

Endolysosomal compartments — LRRK2 influences membrane trafficking through effects on endocytosis, lysosomal function, and autophagy.

Nucleus — Some LRRK2 variants may translocate to the nucleus and influence gene expression.

Signaling Pathways

LRRK2 interfaces with numerous signaling pathways relevant to neurodegeneration:

MAPK signaling — LRRK2 can activate ERK and p38 pathways, influencing cell survival and stress responses.
NF-κB signaling — LRRK2 regulates NF-κB activation, connecting it to neuroinflammation.
Wnt signaling — LRRK2 affects β-catenin degradation and Wnt target gene expression.
mTOR signaling — LRRK2 influences mTOR pathway activity and autophagy regulation.

LRRK2 in Parkinson's Disease Pathogenesis

Cellular Mechanisms

LRRK2 pathogenic mutations lead to neurodegeneration through multiple interconnected mechanisms[@izzard2024]:

Mitochondrial Dysfunction

LRRK2 mutations impair mitochondrial function through several mechanisms:

Decreased mitochondrial complex I activity
Enhanced mitochondrial DNA damage
Impaired mitochondrial dynamics (fusion/fission imbalance)
Defective mitophagy leading to accumulation of damaged mitochondria
Reduced mitochondrial respiration capacity

These deficits are particularly consequential in dopaminergic neurons due to their high metabolic demands and reliance on mitochondrial function for survival[@sanders2014].

Protein Homeostasis Impairment

LRRK2 mutations affect protein quality control systems:

Altered autophagy-lysosome pathway function
Impaired proteasomal degradation
Enhanced aggregation of α-synuclein
Disrupted endolysosomal trafficking

The convergence of LRRK2 dysfunction with α-synuclein pathology is a key feature of PD, with LRRK2 potentially accelerating α-synuclein aggregation and propagation[@bonet2024].

Neuroinflammation

LRRK2 is prominently expressed in microglia, and LRRK2 mutations enhance neuroinflammatory responses:

Increased microglial activation
Enhanced pro-inflammatory cytokine production
Elevated NF-κB signaling
Increased expression of inflammatory mediators

This bidirectional relationship between LRRK2 and neuroinflammation creates a vicious cycle that drives progressive neurodegeneration[@gomez2023].

Synaptic Dysfunction

At synaptic terminals, LRRK2 mutations lead to:

Impaired synaptic vesicle cycling
Reduced dopamine release
Altered synaptic plasticity
Disrupted axonal transport of synaptic proteins

These deficits may precede and contribute to neuronal loss in PD models.

Interaction with α-Synuclein

The relationship between LRRK2 and α-synuclein represents a critical intersection in PD pathogenesis:

LRRK2 can phosphorylate α-synuclein at Ser129, a modification associated with pathological aggregation

LRRK2 mutations enhance α-synuclein aggregation and toxicity in cellular and animal models

α-synuclein inclusions frequently contain LRRK2 in PD brains

LRRK2 activity may influence the spread of α-synuclein pathology through effects on cellular uptake and clearance mechanisms

This interaction suggests that combined targeting of LRRK2 and α-synuclein may provide synergistic therapeutic benefit.

Interaction with Tau

LRRK2 also interacts with tau protein pathology:

LRRK2 can phosphorylate tau at multiple sites

LRRK2 mutations enhance tau pathology in model systems

LRRK2 and tau pathologies co-occur in some PD cases

The relationship may be bidirectional, with tau pathology influencing LRRK2 function

Clinical Features of LRRK2-Associated Parkinson's Disease

Phenotype

Patients with LRRK2-associated PD generally present with typical idiopathic PD features:

Age of onset: Mean age 55-65 years, similar to sporadic PD
Motor symptoms: Resting tremor, bradykinesia, rigidity, and postural instability
Good levodopa response: Patients typically respond well to dopaminergic therapy
Disease progression: Variable but generally similar to idiopathic PD
Non-motor symptoms: Sleep disturbances, depression, and hyposmia are common

However, some clinical differences have been reported[@schneider2023]:

Tremor: May be less prominent as an initial symptom
Cognitive dysfunction: May be less frequent or delayed compared to some other genetic forms
Pyramidal signs: Some families with LRRK2 mutations show additional pyramidal tract involvement

Imaging Findings

Neuroimaging in LRRK2-PD shows typical patterns:

DaTscan: Reduced dopamine transporter binding in striatum, similar to idiopathic PD
MRI: Generally normal, no specific degenerative patterns
PET: Variable findings depending on the specific tracer

Penetrance

LRRK2 mutations show incomplete and age-dependent penetrance:

G2019S: Approximately 30% by age 60, 70% by age 80
Some GTPase domain mutations show higher penetrance
Penetrance is modified by genetic background, environmental factors, and potentially epigenetic mechanisms

Diagnosis and Genetic Testing

Genetic Testing

Genetic testing for LRRK2 mutations is recommended for:

Patients with early-onset PD (<50 years) and family history

Patients with typical PD but family history suggesting autosomal dominant inheritance

Specific populations with high mutation prevalence (e.g., North African, Ashkenazi Jewish)

Patients with atypical features suggesting genetic etiology

Biomarkers

Currently, there are no validated LRRK2-specific biomarkers for diagnosis or disease monitoring. However, research is ongoing in several areas:

LRRK2 kinase activity in cerebrospinal fluid (CSF)
Phospho-LRRK2 levels as a potential pharmacodynamic marker
Neurofilament light chain (NfL) as a general neurodegeneration marker

Therapeutic Approaches

LRRK2 Kinase Inhibitors

The primary therapeutic strategy for LRRK2-PD is developing small molecule kinase inhibitors that reduce LRRK2 activity. Several compounds have entered clinical development[@insinga2024]:

DNL151 (Denali Therapeutics) — A brain-penetrant LRRK2 inhibitor that has completed Phase 1 trials showing target engagement and tolerability.

DNL151/BMS-986467 — A collaboration between Denali and Bristol Myers Squibb advancing multiple LRRK2 inhibitor candidates.

BAY 1436032 — Another LRRK2 inhibitor in development.

Challenges include:

Achieving adequate brain penetration
Maintaining peripheral kinase inhibition for safety monitoring
Managing side effects from LRRK2 inhibition in peripheral tissues (kidney, lung)
Demonstrating disease modification in clinical trials

Other Therapeutic Strategies

Antisense oligonucleotides (ASOs) — Targeting LRRK2 mRNA to reduce protein expression. Companies like Ionis have developed ASO candidates.

Gene therapy approaches — Using viral vectors to deliver therapeutic genes or CRISPR-based approaches to correct mutations.

Disease-modifying approaches beyond kinase inhibition:

Modulators of LRRK2 GTPase activity
Targeting protein-protein interactions
Enhancing autophagy and lysosomal function
Combination therapies targeting downstream pathways

Clinical Trials

Several clinical trials are ongoing or planned:

LRRK2 inhibitor trials in healthy volunteers and PD patients
Studies examining biomarkers of target engagement
Natural history studies tracking LRRK2-PD progression

LRRK2 and the Immune System

Beyond its role in neurons, LRRK2 has important functions in immune cells, creating a bidirectional relationship with neuroinflammation[@singel2024]:

Microglial Function

LRRK2 is highly expressed in microglia, where it:

Regulates inflammatory cytokine production
Influences microglial activation states
Affects phagocytic activity
Modulates inflammatory responses to injury

Peripheral Immune System

LRRK2 variants have been associated with:

Altered immune cell function
Changes in cytokine production
Potential links to inflammatory diseases

Therapeutic Implications

The immune functions of LRRK2 suggest that:

Anti-inflammatory therapies may provide benefit in LRRK2-PD

Peripheral immune markers may serve as biomarkers

Targeting neuroinflammation could complement direct LRRK2 inhibition

Animal Models

Several animal models have been developed to study LRRK2-PD[@esteban2022]:

Rodent Models

Transgenic mice expressing wild-type or mutant LRRK2
Knock-in mice with pathogenic LRRK2 mutations
LRRK2 knockout mice to understand loss-of-function effects

These models show variable phenotypes including:

Locomotor abnormalities
Neurochemical changes
Protein aggregation
Neuroinflammation
Mitochondrial deficits

Non-Mammalian Models

C. elegans models for high-throughput screening
Zebrafish models for developmental studies

Limitations

Current models have limitations:

Incomplete replication of human PD phenotype
Lack of robust dopaminergic neuron loss in most models
Species-specific differences in LRRK2 function

Future Directions

Key questions remaining in the field include:

Mechanism of pathogenesis: How do specific mutations lead to neurodegeneration?

Normal function: What is the physiological role of LRRK2 in neurons?

Biomarkers: Can we develop LRRK2-specific biomarkers for clinical use?

Therapeutic windows: What is the optimal level of LRRK2 inhibition for benefit?

Combination therapies: What other targets should be combined with LRRK2 inhibition?

Patient selection: Which patients are most likely to benefit from LRRK2-targeted therapies?

References

[Paisan-Ruiz & Lewis, LRRK2: cause, consequence, and cause again in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30559311/)

[Walls et al., Structure and function of LRRK2 (2024)](https://doi.org/10.1042/BST20240345)

[Izzat et al., LRRK2 kinase activity and Parkinson's disease: from mechanisms to therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38942812/)

[Taylor et al., Targeting LRRK2 in Parkinson's disease: progress and challenges (2024)](https://pubmed.ncbi.nlm.nih.gov/38795621/)

[Greggio & Cookson, LRRK2 mutations and Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22893124/)

[Singleton et al., LRRK2 Pathogenesis and the Promise of Targeted Therapies (2017)](https://pubmed.ncbi.nlm.nih.gov/28625493/)

[Sanders et al., LRRK2 mutations cause mitochondrial DNA damage in fibroblasts (2014)](https://pubmed.ncbi.nlm.nih.gov/24333099/)

[Esteban et al., LRRK2-associated Parkinson's disease: insights from animal models (2022)](https://pubmed.ncbi.nlm.nih.gov/35411052/)

[Bonet et al., LRRK2 and alpha-synuclein co-pathology in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38715234/)

[Chen et al., LRRK2 regulates mitochondrial dynamics and mitophagy in dopaminergic neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35675879/)

[Hertz et al., LRRK2 kinase inhibitors: a new wave of Parkinson's disease therapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35768423/)

[Gomez et al., LRRK2 mutations and neuroinflammation in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37452341/)

[Kalinderi et al., LRRK2 mutations in Greek Parkinson's disease patients (2022)](https://pubmed.ncbi.nlm.nih.gov/34996023/)

[Riviere et al., LRRK2 founder mutations in North African patients with PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35281452/)

[Schneider et al., LRRK2-associated Parkinson's disease: clinical features and treatment outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/36951782/)

[West et al., ATP-binding pocket mutations in LRRK2 define a novel Kinase domain (2014)](https://pubmed.ncbi.nlm.nih.gov/24452399/)

[Singel et al., LRRK2 and the immune system: a bidirectional relationship (2024)](https://pubmed.ncbi.nlm.nih.gov/38212209/)

[Schmidt et al., Cryo-EM structure of LRRK2 and its pathogenic mutants (2023)](https://pubmed.ncbi.nlm.nih.gov/37217834/)

[Yang et al., LRRK2 and membrane trafficking in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37004521/)

[Insinga et al., LRRK2 kinase inhibitors in clinical trials: current status (2024)](https://doi.org/10.1038/s41582-024-00856-2)

External Links

[Allen Human Brain Atlas](https://brain-map.org/) — LRRK2 gene expression in human brain
[Allen Brain Atlas: LRRK2 Expression](https://human.brain-map.org/microarray/search/show?search_term=LRRK2): Regional gene expression data in human brain

📖 View canonical wiki page →

LRRK2 (Leucine-Rich Repeat Kinase 2) — Comprehensive Gene Review

LRRK2 (Leucine-Rich Repeat Kinase 2)

Overview

LRRK2 (Leucine-Rich Repeat Kinase 2)

Overview

Gene Structure and Mutations

Genomic Organization

Pathogenic Mutations

Risk Variants

Protein Structure and Function

Domain Architecture

Biological Functions

Signaling Pathways

LRRK2 in Parkinson's Disease Pathogenesis

Cellular Mechanisms

Interaction with α-Synuclein

Interaction with Tau

Clinical Features of LRRK2-Associated Parkinson's Disease

Phenotype

Imaging Findings

Penetrance

Diagnosis and Genetic Testing

Genetic Testing

Biomarkers

Therapeutic Approaches

LRRK2 Kinase Inhibitors

Other Therapeutic Strategies

Clinical Trials

LRRK2 and the Immune System

Microglial Function

Peripheral Immune System

Therapeutic Implications

Animal Models

Rodent Models

Non-Mammalian Models

Limitations

Future Directions

See Also

References

External Links